Sygnature Discovery wins Outstanding Achievement Award

Sygnature Discovery have been named as the winner of the Outstanding Achievement award at the Medilink East Midlands Business Awards 2019.

The Medilink Business Awards aim is to highlight the best of the best in the life sciences sector with 7 categories, start-up, export achievement, delivering innovation into health and care, innovation, outstanding achievement, deal of the year and one to watch. The awards ceremony took place on 5th December 2019 at the Radisson Blu East Midlands Airport. The evening began with a networking drinks reception, followed by dinner and the awards presentation by stand-up comedian Jimmy McGhie.

Sygnature were finalist for 2 awards, Outstanding Achievement and Deal of the Year, for the acquisition of the leading preclinical CRO RenaSci. The Outstanding Achievement award was received by Sygnature Discovery’s Dr Paul Clewlow, Senior VP, Business Development, and Anders Lindstrom, Director of Marketing. The Award was sponsored by Pure Drug Safety.

Paul commented: “We are very pleased and privileged to have won the Outstanding Achievement Award. Our aim is to deliver drug candidates and to enable pharmaceutical customers to succeed in developing new treatments ultimately to benefit patients with serious diseases. This award is a great recognition of our track record as well the ability, diligence and dedication of Sygnature Discovery and the science we do.”

The winners are shortlisted for the national Medilink UK Healthcare Business Awards which will take place on the 1st April 2020.

If you have any questions, would like to find out more about Sygnature Discovery or drug discovery in general then we’d love to hear from you. You can get in touch by using any of the contact forms or by emailing us at info@sygnaturediscovery.com.

Latest News

View All

Sygnature Discovery goes for global industry recognition…

First patients dosed in Phase 1a clinical…

Sygnature Discovery Appoints Industry Leaders To Board…

Sygnature Discovery invests £3.75M in Compound Management…